Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 0 224 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE.
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 0 224 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER vs MAGNESIUM SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose provides a source of calories and fluid for cellular metabolism. Sodium chloride and potassium chloride replace electrolyte deficits and maintain acid-base balance.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
IV infusion; rate determined by fluid and electrolyte requirements. Typical adult dose: 1000-2000 mL per 24 hours, administered at 40-80 mL/hour.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
None Documented
None Documented
Dextrose: <1 minute (rapid uptake into cells); potassium: ~4-6 hours in a 70 kg adult with normal renal function; chloride: variable, follows sodium kinetics.
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Excretion is primarily renal for potassium and chloride; dextrose is metabolized to CO2 and water. Potassium: >90% excreted in urine; chloride: >95% renally absorbed and excreted; dextrose: not excreted unchanged.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Category A/B
Category C
Electrolyte
Electrolyte